Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Oct;30(4):527–536. doi: 10.1111/j.1365-2125.1990.tb03810.x

Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.

D Currie 1, R V Lewis 1, D G McDevitt 1, A N Nicholson 1, N A Wright 1
PMCID: PMC1368242  PMID: 2291867

Abstract

1. Central effects of single doses of captopril (12.5, 25 and 50 mg) were studied in fourteen healthy male subjects. Two placebos and an active control drug, oxazepam (15 mg), were included, together with a single dose of atenolol (100 mg). The drugs were administered double-blind at 11.00 h, and performance and subjective feelings were assessed before and from 1.5-2.5 h and 3.5-4.5 h after ingestion. 2. Performance was assessed using digit symbol substitution, continuous attention, letter cancellation, choice reaction time, finger tapping, immediate and short-term memory, together with critical flicker fusion and two flash fusion. Subjects assessed their mood and well-being on a series of 12 visual analogue scales. 3. Captopril did not impair performance on any of the tests, but improved short-term memory (P less than 0.05) and increased the number of letters cancelled (P less than 0.05). Oxazepam reduced the number of substitutions completed in the digit symbol test (P less than 0.01), accuracy on continuous attention (P less than 0.05), number of letters cancelled (P less than 0.05), and rate of finger tapping (P less than 0.05), and increased choice reaction time (P less than 0.001). Atenolol reduced the rate of finger tapping (P less than 0.05), but increased the number of letters cancelled (P less than 0.05). 4. No effects on mood or on subjective feelings were evident with captopril. Oxazepam reduced subjective alertness (P less than 0.05), and atenolol increased feelings of sleepiness (P less than 0.05). 5. Although these observations suggest that central effects may exist with captopril, no adverse consequences have been established on performance or on subjective assessment of mood. Captopril may, therefore, be an appropriate drug for hypertensive patients engaged in skilled activity.

Full text

PDF
530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baranowska D., Braszko J. J., Wiśniewski K. Effect of angiotensin II and vasopressin on acquisition and extinction of conditioned avoidance in rats. Psychopharmacology (Berl) 1983;81(3):247–251. doi: 10.1007/BF00427272. [DOI] [PubMed] [Google Scholar]
  2. Bradley C. M., Nicholson A. N. Effects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man. Br J Clin Pharmacol. 1986 Nov;22(5):507–512. doi: 10.1111/j.1365-2125.1986.tb02928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bradley C. M., Nicholson A. N. Studies on performance with aspirin and paracetamol and with the centrally acting analgesics meptazinol and pentazocine. Eur J Clin Pharmacol. 1987;32(2):135–139. doi: 10.1007/BF00542185. [DOI] [PubMed] [Google Scholar]
  4. Braszko J. J., Wiśniewski K. Effect of angiotensin II and saralasin on motor activity and the passive avoidance behavior of rats. Peptides. 1988 May-Jun;9(3):475–479. doi: 10.1016/0196-9781(88)90150-7. [DOI] [PubMed] [Google Scholar]
  5. Cohen M. L., Kurz K. Captopril and MK-421: stability on storage, distribution to the central nervous system, and onset of activity. Fed Proc. 1983 Feb;42(2):171–175. [PubMed] [Google Scholar]
  6. Croog S. H., Levine S., Sudilovsky A., Baume R. M., Clive J. Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. Arch Intern Med. 1988 Apr;148(4):788–794. [PubMed] [Google Scholar]
  7. Croog S. H., Levine S., Testa M. A., Brown B., Bulpitt C. J., Jenkins C. D., Klerman G. L., Williams G. H. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986 Jun 26;314(26):1657–1664. doi: 10.1056/NEJM198606263142602. [DOI] [PubMed] [Google Scholar]
  8. Croog S. H., Sudilovsky A., Levine S., Testa M. A. Work performance, absenteeism and antihypertensive medications. J Hypertens Suppl. 1987 Feb;5(1):S47–S54. [PubMed] [Google Scholar]
  9. Curran H. V. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol. 1986 Oct;23(2):179–213. doi: 10.1016/0301-0511(86)90081-5. [DOI] [PubMed] [Google Scholar]
  10. Currie D., Lewis R. V., McDevitt D. G., Nicholson A. N., Wright N. A. Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood. Br J Clin Pharmacol. 1988 Aug;26(2):121–128. doi: 10.1111/j.1365-2125.1988.tb03378.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Evered M. D., Robinson M. M., Richardson M. A. Captopril given intracerebroventricularly, subcutaneously or by gavage inhibits angiotensin-converting enzyme activity in the rat brain. Eur J Pharmacol. 1980 Dec 19;68(4):443–449. doi: 10.1016/0014-2999(80)90419-7. [DOI] [PubMed] [Google Scholar]
  12. Frcka G., Lader M. Psychotropic effects of repeated doses of enalapril, propranolol and atenolol in normal subjects. Br J Clin Pharmacol. 1988 Jan;25(1):67–73. doi: 10.1111/j.1365-2125.1988.tb03283.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ganten D., Speck G. The brain renin-angiotensin system: a model for the synthesis of peptides in the brain. Biochem Pharmacol. 1978;27(20):2379–2389. doi: 10.1016/0006-2952(78)90348-9. [DOI] [PubMed] [Google Scholar]
  14. Hill J. F., Bulpitt C. J., Fletcher A. E. Angiotensin converting enzyme inhibitors and quality of life: the European trial. J Hypertens Suppl. 1985 Nov;3(2):S91–S94. [PubMed] [Google Scholar]
  15. Köller M., Krause H. P., Hoffmeister F., Ganten D. Endogenous brain angiotensin II disrupts passive avoidance behavior in rats. Neurosci Lett. 1979 Sep;14(1):71–75. doi: 10.1016/0304-3940(79)95346-1. [DOI] [PubMed] [Google Scholar]
  16. Lichter I., Richardson P. J., Wyke M. A. Differential effects of atenolol and enalapril on memory during treatment for essential hypertension. Br J Clin Pharmacol. 1986 Jun;21(6):641–645. doi: 10.1111/j.1365-2125.1986.tb05228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Morgan J. M., Routtenberg A. Angiotensin injected into the neostriatum after learning disrupts retention performance. Science. 1977 Apr 1;196(4285):87–89. doi: 10.1126/science.402696. [DOI] [PubMed] [Google Scholar]
  18. Nicholson A. N., Wright N. A., Zetlein M. B., Currie D., McDevitt D. G. Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway. Br J Clin Pharmacol. 1988 Aug;26(2):129–141. doi: 10.1111/j.1365-2125.1988.tb03379.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nicholson A. N., Wright N. A., Zetlein M. B., Currie D., McDevitt D. G. Central effects of the angiotensin-converting enzyme inhibitor, captopril. II. Electroencephalogram and body sway. Br J Clin Pharmacol. 1990 Oct;30(4):537–546. doi: 10.1111/j.1365-2125.1990.tb03811.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Olajide D., Lader M. Psychotropic effects of enalapril maleate in normal volunteers. Psychopharmacology (Berl) 1985;86(3):374–376. doi: 10.1007/BF00432232. [DOI] [PubMed] [Google Scholar]
  21. Phillips M. I. Angiotensin in the brain. Neuroendocrinology. 1978;25(6):354–377. doi: 10.1159/000122756. [DOI] [PubMed] [Google Scholar]
  22. Pupita F., Ansuini R., Belogi M., Campolucci G., Gaggi S., Pupita G. Life quality in patients under hypotensive treatment. Int J Clin Pharmacol Res. 1987;7(1):13–17. [PubMed] [Google Scholar]
  23. Ramsay D. J. The brain renin angiotensin system: a re-evaluation. Neuroscience. 1979;4(3):313–321. doi: 10.1016/0306-4522(79)90096-4. [DOI] [PubMed] [Google Scholar]
  24. Rosseel M. T., Belpaire F. M., Bekaert I., Bogaert M. G. High-performance liquid chromatographic determination of metoprolol in plasma. J Pharm Sci. 1982 Jan;71(1):114–115. doi: 10.1002/jps.2600710128. [DOI] [PubMed] [Google Scholar]
  25. Sabel B. A., Kardon G. B., Stein D. G. Behavioral effects of intracerebral injections of renin and captopril in intact and brain-damaged rats. Brain Res Bull. 1983 Dec;11(6):637–642. doi: 10.1016/0361-9230(83)90005-9. [DOI] [PubMed] [Google Scholar]
  26. Sharma H. S. Effect of captopril (a converting enzyme inhibitor) on blood-brain barrier permeability and cerebral blood flow in normotensive rats. Neuropharmacology. 1987 Jan;26(1):85–92. doi: 10.1016/0028-3908(87)90049-9. [DOI] [PubMed] [Google Scholar]
  27. Winkler H., Ried W., Lemmer B. High-performance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue. J Chromatogr. 1982 Mar 12;228:223–234. doi: 10.1016/s0378-4347(00)80435-1. [DOI] [PubMed] [Google Scholar]
  28. Zubenko G. S., Nixon R. A. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry. 1984 Jan;141(1):110–111. doi: 10.1176/ajp.141.1.110. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES